Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis

(2017) Bimal Bhindi et al.   EUROPEAN UROLOGY

Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study

(2016) Jim C. Hu et al.   EUROPEAN UROLOGY

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

(2016) Ming Yin et al.   ONCOLOGIST

Knowledge of the Costs of Diagnostic Imaging: A Survey of Physician Trainees at a Large Academic Medical Center

(2016) Arvind Vijayasarathi et al.   Journal of the American College of Radiology

Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma

(2016) David Liu et al.   JAMA Oncology

ReCAP: Cost Differential of Chemotherapy for Solid Tumors

(2016) Hasan Nadeem et al.   Journal of Oncology Practice

The Myth Regarding the High Cost of End-of-Life Care

(2015) Melissa D. Aldridge et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides

(2015) Zachary D. Reardon et al.   EUROPEAN UROLOGY

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

(2015) Elizabeth R. Plimack et al.   EUROPEAN UROLOGY

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma

(2015) Alexander S. Baras et al.   PLoS One

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer

(2014) Scott M. Stevenson et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

(2014) E. M. Van Allen et al.   Cancer Discovery

Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy

(2013) Shahrokh F. Shariat et al.   BJU INTERNATIONAL

Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

(2013) Stephen H. Culp et al.   JOURNAL OF UROLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer Database

(2013) Harras B. Zaid et al.   UROLOGY

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer

(2010) Guru Sonpavde et al.   JOURNAL OF UROLOGY

CT Colonography to Screen for Colorectal Cancer and Aortic Aneurysm in the Medicare Population: Cost-Effectiveness Analysis

(2009) Perry J. Pickhardt et al.   AMERICAN JOURNAL OF ROENTGENOLOGY